This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Eli Lilly and Company. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovations of Jeffrey A. Peterson
Introduction
Jeffrey A. Peterson is a notable inventor based in Carmel, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of FGFR3 inhibitors. His work is essential for advancing treatments for various diseases associated with FGFR3.
Latest Patents
One of Peterson's key patents is focused on cocrystalline forms of FGFR3 inhibitors. This patent, which includes 1 patent, provides innovative cocrystalline forms of FGFR3 inhibitors combined with gallic acid or nicotinamide coformers. These formulations are useful in the treatment and prevention of diseases that can be treated with FGFR3 inhibitors, including FGFR3-associated diseases and disorders.
Career Highlights
Jeffrey A. Peterson is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role at Eli Lilly has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.
Collaborations
Throughout his career, Peterson has collaborated with talented individuals such as David Andrew Coates and Lori Raquel Hilden. These collaborations have further enhanced the impact of his work in the field.
Conclusion
Jeffrey A. Peterson's innovative contributions to the development of FGFR3 inhibitors highlight his importance as an inventor in the pharmaceutical industry. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile